Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of CF101 plus methotrexate in active rheumatoid arthritis
2007-006527-13Phase 2Withdrawn
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CF101 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR20 response rate. Planned start Jun 2008; status: withdrawn.
02
Drugs
piclidenoson
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-006527-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006527-13.